División Medicina Experimental, Academia Nacional de Medicina, Buenos Aires, Argentina.
Cancer Lett. 2012 Nov 28;324(2):133-41. doi: 10.1016/j.canlet.2012.05.021. Epub 2012 May 22.
Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants. This phenomenon has been described in human and animal systems and it can be generated by both immunogenic and non-immunogenic tumors. The relevance of CR to the mechanisms of metastases control has been highlighted by numerous observations showing that the removal of human and murine tumors may be followed by an abrupt increase in metastatic growth, suggesting that a primary tumor may exert a controlling action on its metastases which could be considered as secondary tumor implants developed spontaneously during the primary tumor growth. A more profound understanding of the different mechanisms claimed to be associated with the phenomenon of CR could contribute to develop new and more harmless means to manage malignant diseases, especially by limiting the development of metastases that arise after resection of primary tumors or after other stressors that may promote the escape of metastases from dormancy.
伴随肿瘤抵抗(CR)是一种现象,即肿瘤宿主对继发性肿瘤植入物的生长具有抗性。这种现象在人类和动物系统中都有描述,它可以由免疫原性和非免疫原性肿瘤产生。CR 对转移控制机制的相关性已被大量观察结果所强调,这些观察结果表明,人类和鼠类肿瘤的切除可能随后导致转移性生长的突然增加,这表明原发性肿瘤可能对其转移施加控制作用,这些转移可以被认为是在原发性肿瘤生长过程中自发发展的继发性肿瘤植入物。对与 CR 现象相关的不同机制的更深入理解,可以有助于开发新的、更无害的方法来治疗恶性疾病,特别是通过限制原发性肿瘤切除或其他可能促进转移从休眠中逃脱的应激源后出现的转移的发展。